Opus Genetics, Inc. (IRD)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Financial Position (from SEC Filings)

$60.0M
Cash & Equivalents
$12.7M
Quarterly Burn Rate
14 mo
Est. Cash Runway
$337M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT05616793 Safety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD) and Non-interv... PHASE2 Recruiting 22

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for IRD.

SEC EDGAR Filings

All SEC filings for Opus Genetics, Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.